Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

On average, stocks trade for an average of just 11.6 years, with the median or midpoint tenure even lower at 6.8 years. Of the nearly 29,100 stocks analyzed, only 31 made it through all 98 years ...

The study marks the first direct comparison between digital PCR and NGS-based dd-cfDNA tests in kidney transplant patients.

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

The latest study builds on some of his earlier research that also revealed the rarity of truly great-performing stocks. "I was indeed surprised when I first documented that a slight majority of ...

The results indicated that subjects who switched from alglucosidase alfa to cipa+mig generally achieved improvements or ...

The stock market has generated high returns over time, but picking winners isn't easy, according to an ASU study that estimated one in two stocks lose money. Only a handful emerge as big winners.

The study found that stocks, bonds, and options strategies could have more correlated risk than is evident on the surface. And that link could strengthen as you deploy certain variables across ...